Formulary Committee Membership Will Be Scrutinized By OIG, Attorney Says
Physicians who sit on formulary committees may be a focus of heightened scrutiny under the HHS Office of the Inspector General's compliance guide due to possible conflict-of-interest issues
You may also be interested in...
Education and research grants to purchasers from pharmaceutical manufacturers may violate the anti-kickback statute, the HHS Inspector General's compliance guide contends
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials